Stockscreener 앱 받기
4.37
6.07%
0.25
시간 외 거래:
4.18
-0.19
-4.35%
전일 마감가:
$4.12
열려 있는:
$4.12
하루 거래량:
2.26M
Relative Volume:
0.50
시가총액:
$533.15M
수익:
$58.36M
순이익/손실:
$-25.72M
주가수익비율:
-12.00
EPS:
-0.3641
순현금흐름:
$-24.91M
1주 성능:
+5.56%
1개월 성능:
+9.25%
6개월 성능:
-13.64%
1년 성능:
+60.07%
1일 변동 폭
$4.12
$4.40
1주일 범위
$3.86
$4.40
52주 변동 폭
$2.12
$7.55
Aquestive Therapeutics Inc Stock (AQST) Company Profile
명칭
Aquestive Therapeutics Inc
전화
908-941-1900
주소
30 TECHNOLOGY DRIVE, WARREN, NJ
Compare AQST vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
4.37 | 502.65M | 58.36M | -25.72M | -24.91M | -0.3641 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.96 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.47 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.91 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
490.21 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2024-12-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-05-10 | 개시 | Leerink Partners | Outperform |
| 2024-04-11 | 개시 | Piper Sandler | Overweight |
| 2024-03-28 | 개시 | Raymond James | Outperform |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2019-04-22 | 개시 | H.C. Wainwright | Buy |
| 2019-01-03 | 개시 | Lake Street | Buy |
| 2018-08-20 | 개시 | JMP Securities | Mkt Outperform |
| 2018-08-20 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Aquestive Therapeutics Inc 주식(AQST)의 최신 뉴스
A Preview Of Aquestive Therapeutics's Earnings - Benzinga
AQST Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aquestive Therapeutics, Inc.Common Stock (NQ: AQST - The Chronicle-Journal
Aquestive Therapeutics Inc (AQST) - MSN
AQST INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics - PR Newswire
Aquestive Therapeutics Inc. (AQST) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Aquestive Therapeutics Touts Anaphylm, Targets Q3 FDA Resubmission After CRL at Oppenheimer Conference - MarketBeat
Lake Street adjusts Aquestive Therapeutics, Inc. (AQST) valuation model on expected approval delay - MSN
INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics - GlobeNewswire
Aquestive Highlights Strategy, Pipeline and Risk Disclosures - TipRanks
Aquestive Therapeutics files investor presentation detailing Anaphylm plan, CRL resubmission timeline and cash position - TradingView
Aquestive Therapeutics Forms Death Cross, Signaling Potential Bearish Trend - Markets Mojo
Aquestive Therapeutics to Participate in Upcoming March Investor Conferences - Investing News Network
Aquestive Therapeutics (AQST) to Release Earnings on Wednesday - MarketBeat
AQST INVESTIGATION ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics - marketscreener.com
Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET - Investing News Network
Aquestive Therapeutics to Report Fourth Quarter 2025 - GlobeNewswire
Lake Street Adjusts Aquestive Therapeutics, Inc. (AQST) Valuation Model on Expected Approval Delay - Insider Monkey
Aquestive Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference - Bitget
Pharma company Aquestive joins Oppenheimer’s virtual healthcare investor event - Stock Titan
625,000 Shares in Aquestive Therapeutics, Inc. $AQST Acquired by Aberdeen Group plc - MarketBeat
Is Aquestive Therapeutics Inc. forming a bullish divergenceJuly 2025 Setups & Free High Return Stock Watch Alerts - mfd.ru
Aquestive Therapeutics to Present New Clinical Data on Anaphylm (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual Meeting - Bitget
Aquestive Therapeutics Announces Clinical Results for Anaphylm™ Sublingual Film at AAAAI Annual Meeting - Quiver Quantitative
Allergy film Anaphylm delivers epinephrine without blood pressure dip in study - Stock Titan
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer - The Globe and Mail
Analyst Upgrade: Will Aquestive Therapeutics Inc benefit from government policyQuarterly Growth Report & Weekly High Conviction Ideas - baoquankhu1.vn
Aquestive appoints allergy expert Dr. Greenhawt as chief medical officer - Investing.com
2026-02-18 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Shareholders to Learn More About the Investigation | NDAQ:AQST | Press Release - Stockhouse
Aquestive Therapeutics Appoints Dr. Matthew Greenhawt as Chief Medical Officer - citybiz
Aquestive appoints allergy expert Dr. Greenhawt as chief medical officer By Investing.com - Investing.com Canada
Aquestive Therapeutics Appoints Dr. Matthew Greenhawt as Chief Medical Officer to Advance Anaphylm™ NDA Resubmission - Quiver Quantitative
INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics - Nasdaq
Aquestive Therapeutics: Biology Validated, Packaging PendingA Forensic Analysis Of The Anaphylm CRL - Seeking Alpha
Aquestive Therapeutics Faces FDA Setback for Anaphylm Drug - National Today
AQST SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics - marketscreener.com
AQST SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP - GlobeNewswire
Can Aquestive Therapeutics Inc. stock resist sector downturnsDollar Strength & Weekly Market Pulse Updates - mfd.ru
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc.AQST - PR Newswire
2026-02-12 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Investors to Learn More About the Investigation | NDAQ:AQST | Press Release - Stockhouse
Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics - TMX Newsfile
INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Beh - GuruFocus
Faruqi & Faruqi Investigates Aquestive Therapeutics for Investor Losses - intellectia.ai
Revenue Downgrade: Here's What Analysts Forecast For Aquestive Therapeutics, Inc. (NASDAQ:AQST) - 富途牛牛
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares May Have Slumped 36% But Getting In Cheap Is Still Unlikely - 富途牛牛
Aquestive Therapeutics Inc (AQST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Aquestive Therapeutics Inc 주식 (AQST) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Jung Cassie | Chief Operating Officer |
Oct 15 '25 |
Option Exercise |
3.10 |
25,000 |
77,568 |
308,346 |
| Jung Cassie | Chief Operating Officer |
Oct 15 '25 |
Sale |
7.01 |
67,575 |
473,701 |
240,771 |
| Kraus Carl N | Chief Medical Officer |
Oct 15 '25 |
Sale |
7.00 |
20,272 |
141,904 |
282,475 |
| Boyd Peter E. | See Remarks |
Oct 15 '25 |
Sale |
7.00 |
10,000 |
70,000 |
268,323 |
0.21%
1.77%
자본화:
|
볼륨(24시간):